DK0620215T3 - 1H-indol-3-acetamidderivater som sPLA2-inhibitorer - Google Patents
1H-indol-3-acetamidderivater som sPLA2-inhibitorerInfo
- Publication number
- DK0620215T3 DK0620215T3 DK94302666T DK94302666T DK0620215T3 DK 0620215 T3 DK0620215 T3 DK 0620215T3 DK 94302666 T DK94302666 T DK 94302666T DK 94302666 T DK94302666 T DK 94302666T DK 0620215 T3 DK0620215 T3 DK 0620215T3
- Authority
- DK
- Denmark
- Prior art keywords
- indole
- acetamide derivatives
- spla2 inhibitors
- spla2
- inhibitors
- Prior art date
Links
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 title abstract 2
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 title abstract 2
- ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical class C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4862993A | 1993-04-16 | 1993-04-16 | |
| US20872194A | 1994-03-15 | 1994-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0620215T3 true DK0620215T3 (da) | 1999-12-06 |
Family
ID=26726342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94302666T DK0620215T3 (da) | 1993-04-16 | 1994-04-14 | 1H-indol-3-acetamidderivater som sPLA2-inhibitorer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5684034A (da) |
| EP (1) | EP0620215B1 (da) |
| JP (1) | JPH0725850A (da) |
| KR (1) | KR100317755B1 (da) |
| CN (1) | CN1068588C (da) |
| AT (1) | ATE183503T1 (da) |
| AU (1) | AU676884B2 (da) |
| BR (1) | BR9401482A (da) |
| CA (1) | CA2121323A1 (da) |
| CO (1) | CO4230092A1 (da) |
| CZ (1) | CZ289750B6 (da) |
| DE (1) | DE69420068T2 (da) |
| DK (1) | DK0620215T3 (da) |
| ES (1) | ES2138648T3 (da) |
| FI (1) | FI941767A (da) |
| GR (1) | GR3031783T3 (da) |
| HU (1) | HUT70836A (da) |
| IL (1) | IL109311A0 (da) |
| NO (1) | NO300732B1 (da) |
| NZ (1) | NZ260298A (da) |
| PL (1) | PL181319B1 (da) |
| RU (1) | RU2162463C2 (da) |
| TW (1) | TW268942B (da) |
| UA (1) | UA44218C2 (da) |
| YU (1) | YU20194A (da) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| US6252084B1 (en) | 1994-03-15 | 2001-06-26 | Eli Lilly And Company | 1H-indole-3-acetamide sPLA2 inhibitors |
| DK0675110T3 (da) * | 1994-04-01 | 2002-10-07 | Lilly Co Eli | 1H-indol-3-glyoxylamid-sPLA2-inhibitorer |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| US6214876B1 (en) | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
| WO1998008818A1 (en) * | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| CZ136899A3 (cs) * | 1996-10-30 | 1999-09-15 | Eli Lilly And Company | Substituované tricyklické sloučeniny |
| US6713645B1 (en) * | 1996-10-30 | 2004-03-30 | Eli Lilly And Company | Substituted tricyclics |
| US6569539B2 (en) | 1996-10-30 | 2003-05-27 | Tetra Level Holdings & Finance S.A. | Gas barrier packaging laminate method for production thereof and packaging containers |
| US5919774A (en) * | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| CA2279211A1 (en) * | 1997-02-20 | 1998-08-27 | Shionogi & Co., Ltd. | Indole dicarboxylic acid derivatives |
| ID27280A (id) * | 1998-02-25 | 2001-03-22 | Genetics Inst | Inhibitor-inhibitor dari enzim-enzim fosfolipase |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| PL343007A1 (en) * | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| IL137540A0 (en) * | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| HUP0102981A3 (en) | 1998-03-31 | 2002-10-28 | Shionogi & Co | Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof |
| ID23219A (id) * | 1998-04-17 | 2000-03-30 | Lilly Co Eli | Trisiklik tersubstitusi |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| AU748787B2 (en) | 1998-05-21 | 2002-06-13 | Shionogi & Co., Ltd. | Pyrrolo(1,2-b)pyridazine derivatives having sPLA2 inhibitory effect |
| WO2000007591A1 (en) | 1998-08-03 | 2000-02-17 | Eli Lilly And Company | INDOLE sPLA2 INHIBITORS |
| EP1100492B1 (en) | 1998-08-03 | 2006-05-24 | Eli Lilly & Company | INDOLE sPLA2 INHIBITORS |
| AU6240099A (en) | 1998-08-24 | 2000-03-14 | Susan E Draheim | Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2 |
| EP1157704B1 (en) | 1998-10-14 | 2006-06-14 | Shionogi & Co., Ltd. | Spla2 inhibitors for the treatment of ischaemic reperfusion injury |
| WO2000037472A2 (en) * | 1998-12-22 | 2000-06-29 | Eli Lilly And Company | Substituted pirroloindoles |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| US6703385B1 (en) | 1999-07-19 | 2004-03-09 | Shionogi & Co., Ltd. | Tricyclic compounds having sPLA2-inhibitory activities |
| ATE350367T1 (de) * | 1999-07-19 | 2007-01-15 | Lilly Co Eli | Spla2 inhibitoren |
| US6673781B1 (en) | 1999-08-02 | 2004-01-06 | Shionogi & Co., Ltd. | Tricyclic compounds having sPLA2-inhibitory activities |
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| US6831095B1 (en) | 1999-09-20 | 2004-12-14 | Eli Lilly And Company | Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors |
| DE60032254D1 (de) * | 1999-09-20 | 2007-01-18 | Lilly Co Eli | Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren |
| AU7559600A (en) * | 1999-10-15 | 2001-04-23 | Shionogi & Co., Ltd. | V type and/or x type spla2 inhibitors |
| AU1304801A (en) | 1999-11-15 | 2001-05-30 | Shionogi & Co., Ltd. | Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect |
| DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| US6608059B1 (en) | 2000-06-27 | 2003-08-19 | Smithkline Beecham Corporation | Fatty acid synthase inhibitors |
| AU2001267825A1 (en) | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cirrhosis |
| AU2001267823A1 (en) * | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Compounds exhibiting x-type spla2 inhibiting effect |
| GB0016162D0 (en) * | 2000-06-30 | 2000-08-23 | Cancer Res Campaign Tech | Indole-3-acetic acid derivatives |
| US20050203166A1 (en) * | 2000-06-30 | 2005-09-15 | Cancer Research Technology Limited | Indole-3-acetic acid derivatives |
| CN1450893A (zh) * | 2000-07-14 | 2003-10-22 | 伊莱利利公司 | 治疗脓毒症的方法 |
| IE20010784A1 (en) * | 2000-08-24 | 2003-04-16 | Univ Dublin City | N-benzylindole-3-acetic acid derivatives |
| EP1358156B1 (en) * | 2000-12-18 | 2007-02-21 | Eli Lilly And Company | Benz(g) indoles and their use as spla2 inhibitors |
| CA2430808A1 (en) * | 2000-12-18 | 2002-06-27 | Eli Lilly And Company | Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| TWI314457B (da) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| US6635771B2 (en) | 2001-12-03 | 2003-10-21 | Wyeth | N-benzhydryl indole compounds |
| US7605156B2 (en) | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| US6984735B2 (en) | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
| US7101875B2 (en) | 2001-12-03 | 2006-09-05 | Wyeth | Methods for treating arthritic disorders |
| US6797708B2 (en) | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
| US7713964B2 (en) | 2001-12-03 | 2010-05-11 | Wyeth Llc | Methods for treating asthmatic conditions |
| US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20070161698A1 (en) * | 2003-05-30 | 2007-07-12 | Microbia, Inc. | Modulators of CRTH2 Activity |
| JP2007527397A (ja) * | 2003-07-01 | 2007-09-27 | マイクロバイア インコーポレイテッド | Ｃｏｘ−２及びｆａａｈ阻害剤 |
| WO2005037227A2 (en) * | 2003-10-16 | 2005-04-28 | Microbia, Inc. | Selective cox-2 inhibitors |
| US7417063B2 (en) * | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
| US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
| GT200600228A (es) | 2005-05-27 | 2006-12-26 | Inhibidores de la fosfolipasa a2 citosolica | |
| EP1931632A4 (en) * | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
| AU2006311767A1 (en) | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
| JP2009517341A (ja) * | 2005-11-03 | 2009-04-30 | イリプサ， インコーポレイテッド | Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用 |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| US11033523B2 (en) | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
| CN105384619B (zh) * | 2014-08-22 | 2020-05-29 | 四川海思科制药有限公司 | 一种异丙基苯酚衍生物及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2825734A (en) * | 1955-04-11 | 1958-03-04 | Upjohn Co | Reduction of carbonylic radicals in indolyl-3 compounds |
| US2890223A (en) * | 1956-03-22 | 1959-06-09 | Research Corp | 1-benzyl, 2-methyl, 5-methoxy tryptamine |
| US3242193A (en) * | 1961-03-13 | 1966-03-22 | Merck & Co Inc | Indolyl aliphatic acids |
| US3242163A (en) * | 1961-03-13 | 1966-03-22 | Merck & Co Inc | Indolyl aliphatic acids |
| US3196162A (en) * | 1961-03-13 | 1965-07-20 | Merck & Co Inc | Indolyl aliphatic acids |
| US3242162A (en) * | 1961-03-13 | 1966-03-22 | Merck & Co Inc | Indolyl aliphatic acids |
| US3271416A (en) * | 1961-10-24 | 1966-09-06 | Merck & Co Inc | Indolyl aliphatic acids |
| US3259622A (en) * | 1962-09-07 | 1966-07-05 | Merck & Co Inc | 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids |
| US4428962A (en) * | 1981-10-30 | 1984-01-31 | Schering Corporation | Indoles in treatment of peptic ulcers |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
-
1994
- 1994-04-12 IL IL10931194A patent/IL109311A0/xx unknown
- 1994-04-13 NZ NZ260298A patent/NZ260298A/en unknown
- 1994-04-13 TW TW083103301A patent/TW268942B/zh active
- 1994-04-13 HU HU9401060A patent/HUT70836A/hu unknown
- 1994-04-14 AT AT94302666T patent/ATE183503T1/de not_active IP Right Cessation
- 1994-04-14 CO CO94014981A patent/CO4230092A1/es unknown
- 1994-04-14 BR BR9401482A patent/BR9401482A/pt not_active Application Discontinuation
- 1994-04-14 CZ CZ1994893A patent/CZ289750B6/cs not_active IP Right Cessation
- 1994-04-14 DK DK94302666T patent/DK0620215T3/da active
- 1994-04-14 DE DE69420068T patent/DE69420068T2/de not_active Expired - Fee Related
- 1994-04-14 CA CA002121323A patent/CA2121323A1/en not_active Abandoned
- 1994-04-14 EP EP94302666A patent/EP0620215B1/en not_active Expired - Lifetime
- 1994-04-14 ES ES94302666T patent/ES2138648T3/es not_active Expired - Lifetime
- 1994-04-15 NO NO941361A patent/NO300732B1/no not_active IP Right Cessation
- 1994-04-15 KR KR1019940007935A patent/KR100317755B1/ko not_active IP Right Cessation
- 1994-04-15 PL PL94303028A patent/PL181319B1/pl unknown
- 1994-04-15 RU RU94012930/04A patent/RU2162463C2/ru active
- 1994-04-15 AU AU59492/94A patent/AU676884B2/en not_active Ceased
- 1994-04-15 FI FI941767A patent/FI941767A/fi unknown
- 1994-04-15 YU YU20194A patent/YU20194A/sh unknown
- 1994-04-15 CN CN94104434A patent/CN1068588C/zh not_active Expired - Fee Related
- 1994-04-15 UA UA94005180A patent/UA44218C2/uk unknown
- 1994-04-15 JP JP6077650A patent/JPH0725850A/ja active Pending
-
1995
- 1995-05-05 US US08/435,256 patent/US5684034A/en not_active Expired - Lifetime
-
1999
- 1999-11-08 GR GR990402875T patent/GR3031783T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2121323A1 (en) | 1994-10-17 |
| NO941361D0 (no) | 1994-04-15 |
| EP0620215B1 (en) | 1999-08-18 |
| JPH0725850A (ja) | 1995-01-27 |
| NO941361L (no) | 1994-10-17 |
| IL109311A0 (en) | 1994-07-31 |
| YU20194A (sh) | 1997-09-30 |
| AU676884B2 (en) | 1997-03-27 |
| TW268942B (da) | 1996-01-21 |
| NO300732B1 (no) | 1997-07-14 |
| FI941767A (fi) | 1994-10-17 |
| AU5949294A (en) | 1994-10-20 |
| ES2138648T3 (es) | 2000-01-16 |
| NZ260298A (en) | 1996-05-28 |
| HUT70836A (en) | 1995-11-28 |
| GR3031783T3 (en) | 2000-02-29 |
| RU2162463C2 (ru) | 2001-01-27 |
| ATE183503T1 (de) | 1999-09-15 |
| BR9401482A (pt) | 1994-10-18 |
| DE69420068D1 (de) | 1999-09-23 |
| CN1068588C (zh) | 2001-07-18 |
| CN1098715A (zh) | 1995-02-15 |
| KR100317755B1 (ko) | 2002-08-09 |
| CZ89394A3 (en) | 1994-12-15 |
| DE69420068T2 (de) | 1999-12-23 |
| US5684034A (en) | 1997-11-04 |
| FI941767A0 (fi) | 1994-04-15 |
| CO4230092A1 (es) | 1995-10-19 |
| CZ289750B6 (cs) | 2002-03-13 |
| HU9401060D0 (en) | 1994-07-28 |
| PL181319B1 (pl) | 2001-07-31 |
| EP0620215A1 (en) | 1994-10-19 |
| UA44218C2 (uk) | 2002-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0620215T3 (da) | 1H-indol-3-acetamidderivater som sPLA2-inhibitorer | |
| DK0620214T3 (da) | 1H-indol-3-eddikesyrehydrazid som sPLA2-inhibitorer | |
| DE69527322T2 (de) | 1H-Indol-3-Glyoxylamid sPLA2 Inhibitoren | |
| DK0779271T3 (da) | Naphthylacetamider som sPLA2-inhibitorer | |
| YU200791A (sh) | Trifluorometil 1-karba (1-detia) cefemi |